The Global Health Body Sounds Warning Over Critical Shortage of Obesity Injections

Less than 10% of patients who could benefit from obesity jabs such as Wegovy can access them, states the WHO as it releases its inaugural advice on the medications.

Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for increased and just availability to these injectable treatments.

Per forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention.

"Our latest guidance acknowledges that excess weight is a long-term condition that can be managed with comprehensive and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and logistical bottlenecks are major obstacles to universal access to the injections that can help people shift considerable body mass, says the agency.

GLP-1 Therapy Scarcity

Despite the present best projected outlook, the manufacturing of these medications would only suffice for approximately 100 million people – fewer than 10% of eligible patients, as stated by the health organization.

The advice encourages governments and firms to widen availability, by approaches such as patent sharing.

The intellectual property rights on a key compound – the core component of the drug Wegovy – is set to lapse in a number of nations in 2026.

The Way Weight-Loss Injections Work

These medications mimick a biological compound to slow digestion, curb appetite and increase feelings of fullness so people consume fewer calories.

Individuals usually begin shedding pounds after several weeks of beginning the once-weekly jabs.

Studies points to people may regain a significant portion after a year of discontinuing the medication, as their normal hunger come back.

To be overweight or obese elevates your chance for contracting diseases, such as type 2 diabetes, heart disease, stroke, and specific cancers.

Obesity affects individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, per the WHO.

Kathleen Leonard
Kathleen Leonard

A seasoned media analyst with over a decade of experience covering UK broadcasting and digital trends.